AIM AIM ImmunoTech Inc.
$0.17▲ +1.47%
Healthcare
Other
Volume 196.2K
Avg Volume (10D) 562.3K
Key Metrics & Fundamentals
Market Cap
$6.63M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.15 - 2.55
% vs 50 MA
-18.65%
% vs 200 MA
-66.98%
RSI-14
40.6
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.51
Free Cash Flow
-$2.75M
Gross Rev
$22,000
Gross Profit
$18,000
EBITDA
-$2.21M
COGS
$4,000
Operating Exp
$2.24M
Operating Income
-$2.23M
EBIT
-$2.23M
Pretax Income
-$3.02M
Net Income
-$3.02M
EPS (Diluted)
-0.69
Price & Volume History
Loading chart…
Recent News
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
GlobeNewswire · Oct 7, 2026 9:14 AM ET
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
GlobeNewswire · Oct 5, 2026 9:22 AM ET
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
GlobeNewswire · Oct 1, 2026 9:02 AM ET
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
GlobeNewswire · Sep 30, 2026 8:44 AM ET
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
GlobeNewswire · Sep 22, 2026 8:55 AM ET
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
GlobeNewswire · Sep 9, 2026 9:03 AM ET
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
GlobeNewswire · Sep 2, 2026 8:43 AM ET
AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS FOR AUGUST
CNW Group · Sep 1, 2026 7:00 AM ET
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
GlobeNewswire · Aug 31, 2026 8:51 AM ET
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
GlobeNewswire · Aug 27, 2026 9:01 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See AIM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.